CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain and arm functionality with an increase in arm strength. Final trial results were announced in 1Q16.
Sources: CollPlant; ORTHOWORLD Inc.
CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain...
CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain and arm functionality with an increase in arm strength. Final trial results were announced in 1Q16.
Sources: CollPlant; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.